CDIB Capital portfolio

CDIB Capital has 3 portfolio companies on record at Recent Funding.

Website: cdibcapital.com.

Type: Venture capital.

Portfolio on Recent Funding: 3.

Deals, last 12 months: 0.

Capital in their rounds: $110M.

Latest deal: Aidoc · Jun 16, 2022.

About this page

It is a venture capital firm based in Hong Kong, HK. Its most recent investment on record is Aidoc's $110M Series B+ round in June 2022, alongside Alpha Intelligence Capital, TCV and Synetro Group. By category, its portfolio leans toward Health and bio (2) and Developer tools and cloud (2).

About CDIB Capital

Firm type: Venture capital.

Headquarters: Hong Kong, HK.

Stages: Series A, Series B, Series C.

Sectors: Biotech, Healthtech.

Check size: $1.5M to $100M.

What CDIB Capital invests in

Health and bio · 2 · 67%
Developer tools and cloud · 2 · 67%
Education · 1 · 33%
Commerce and retail · 1 · 33%

How CDIB Capital invests

Stage	Deals	Capital in rounds
Series B+	1 100%	$110M

CDIB Capital portfolio companies

AAidoc$110MSeries B+ · Jun 2022
SShoplinebacker
LLaekna Therapeuticsbacker

Company	Round with CDIB Capital	Total raised	Latest raise
AAidoc Health and bio	Jun 16, 2022 Series B+ · $110M	$373M	Apr 29, 2026 Series B+
SShopline Developer tools and cloud	backer	undisclosed	—
LLaekna Therapeutics Health and bio	backer	$61M	May 18, 2022 Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-09, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Share is of the 1 round on Recent Funding that name CDIB Capital. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists CDIB Capital, which is a subset of its real portfolio. API: /api/v1/investors/cdib-capital (get a free API key). More: the most active VC firms and new venture capital funds.